HIV infection and advanced age: Emerging epidemiological, clinical, and management issues

Ageing Research Reviews

Volumn 3, Issue 1, 2004, Pages 31-54

  Manfredi, Roberto ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Advanced age; Clinical features; Epidemiology; HIV infection; Pharmacologic management; Treatment

Indexed keywords

ABACAVIR; ADEFOVIR; AMPHOTERICIN B; AMPRENAVIR; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; DIDANOSINE; FOSCARNET; HYDROXYUREA; IMIDAZOLE DERIVATIVE; INDINAVIR; ISONIAZID; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PENTAMIDINE; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

AGE DISTRIBUTION; ANTIMICROBIAL ACTIVITY; ATHEROSCLEROSIS; ATTENTION; AVASCULAR NECROSIS; CEREBROVASCULAR DISEASE; CHEMOPROPHYLAXIS; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG DEPENDENCE; DYSLIPIDEMIA; ELDERLY CARE; EVOLUTION; GENE THERAPY; GYNECOMASTIA; HEALTH CARE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; HYPERTENSION; IMMUNE DEFICIENCY; INTERMETHOD COMPARISON; LACTIC ACIDOSIS; LIFE EXPECTANCY; LIPOATROPHY; MEDICAL RECORD; MORBIDITY; MUSCLE INJURY; NEPHROTOXICITY; OPPORTUNISTIC INFECTION; OSTEOPENIA; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; REVIEW; RISK FACTOR; SIDE EFFECT; STEATOSIS; SURVIVAL; THYMUS; THYMUS FUNCTION;

EID: 0842281435     PISSN: 15681637     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arr.2003.07.001     Document Type: Review

References (111)

1. Adeyemi O.M., Badri S.M., Max B., Chinomona N., Barker D. HIV infection in older patients. Clin. Infect. Dis. 36:2003;1347.
2. Adler W.H., Baskar P.V., Chrest F.J., Dorsey-Cooper B., Winchurch R.A., Nagel J.E. HIV infection and aging: mechanisms to explain the accelerated rate of progression in the older patient. Mech. Ageing Dev. 96:1997;137-155.
3. Andrews L., Friedland G. Progress in HIV therapeutics and the challenge of adherence to antiretroviral therapy. Infect. Dis. Clin. N. Am. 14:2000;901-928.
4. Antiretroviral treatment for adult HIV infection in 2002, 2002. Updated recommendations of the International AIDS Society-USA Panel. JAMA 288, 161-178.
5. Balotta C., Violin M., Monno L., Bagnarelli P., Riva C., Facchi G., Berlusconi A., Lippi M., Rusconi S., Clementi M., Galli M., Angarano G., Moroni M. Prevalence of multiple dideoxynucleoside analogue resistance (MddNR) in a multicenter cohort of HIV-1-infected Italian patients with virologic failure. J. Acquir. Immune Defic. Syndr. 24:2000;232-240.
6. Barreiro P., Soriano V., Blanco F., Casimiro C., De la Cruz J.J., Gonzalez-Lahoz J. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS. 14:2000;807-812.
7. Beck E.J., Miners A.H., Tolley K. The cost of HIV treatment and care. A global review. Pharmacoeconomics. 19:2001;13-39.
8. Belanger F., Meyer L., Carré N., Coutellier A., Deveau C. Influence of age at infection on human immunodeficiency virus disease progression to different clinical endpoints: the SEROCO Cohort (1988-1994). Int. J. Epidemiol. 26:1997;1340-1345.
9. Beltz L. Thymic involution and HIV progression. Immunol. Today. 20:1999;429.
10. Brinkman K., Smeitink J.A., Romijn J.A., Reiss P. Mitochondrial toxicity induced by nucleoside analogue reverse-transcriptase inhibitors is a key factor in the patogenesis of antiretroviral therapy-related lipodystrophy. Lancet. 354:1999;112-115.
11. Buss N., Snell P., Bock J., Hsu A., Jorga K. Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration. Br. J. Clin. Pharmacol. 52:2001;255-264.
12. Butt A.A., Dascomb K.K., DeSalvo K.B., Bazzano L., Kissinger P.J., Szerlip H.K. Human immunodeficiency virus infection in elderly patients. S. Med. J. 94:2001;397-400.
13. Call S.A., Saag M.S., Westfall A.O., Rapen J.L., Pham S.V., Tolson J.M., Hellmann N.S., Cloud G.A., Johnson V.A. Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. J. Infect. Dis. 183:2001;401-408.
14. Calza L., Manfredi R., Chiodo F. Statins and fibrates for the treatment of hyperlipidemia in HIV-infected patients receiving HAART. AIDS. 17:2003a;851-859.
15. Calza L., Manfredi R., Farneti B., Chiodo F. Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. Int. J. Antimicrob. Agents. 22:2003b;54-59.
16. Carr A., Samaras K., Burton S. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;F51-F58.
17. Casado J.L., Hertogs K., Ruiz L., Dronda F., Van Cauwenberge A., Arno A., Garcia-Arata I., Bloor S., Bonyoch A., Blazquez J., Clotet B., Larder B. Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen. AIDS. 14:2000;F1-F7.
18. Centers for Disease Control and Prevention, 1994. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 41, 1-9.
19. Chaisson R.E., Keruly J.C., Moore R.D. Race, sex, drug use, and progression of human immunodeficiency virus disease. N. Engl. J. Med. 333:1995;751-756.
20. Chesney M.A. Factors affecting adherence to antiretroviral therapy. Clin. Infect. Dis. 30(Suppl. 2):2000;171-176.
21. Cloud G.C., Browne R., Salooja N., McLean K.A. Newly diagnosed HIV infection in an octgenarian: the elder are not "immune" Age Ageing. 32:2003;353-354.
22. Deeks S.G., Barbour J.D., Martin J.N., Swanson M.S., Grant R.M. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J. Infect. Dis. 181:2000;946-953.
23. Descamps D., Flandre P., Calvez V., Peytavin G., Meiffredy V., Collin G., Delaugere C., Robert-Dalmas S., Bazin B., Aboulker J.P., Pialoux G., Raffi F., Brun-Vezinet F. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA. 283:2000;205-211.
24. Douek D.C., Koup R.A. Evidence for thymic function in the elderly. Vaccine. 18:2000;1638-1641.
25. Douek D.C., McFarland R.D., Keiser P.H., Gage E.A., Massey J.M., Haynes B.F., Polis M.A., Haase A.T., Feinberg M.B., Sullivan J.L., Jamieson B.D., Zack J.A., Picker L.J., Koup R.A. Changes in thymic function with age and during the treatment of HIV infection. Nature. 396:1998;690-695.
26. Dubé M.P., Sprecher D., Keith Henry W., Aberg J.A., Torriani F.J., Hodis H.N., Schouten J., Levin J., Myers G., Zackin R., Nevin T., Currier J.S. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the Adults AIDS Clinical Trial Group Cardiovascular Disease Focus Group. Clin. Infect. Dis. 31:2000;1216-1224.
27. Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., Montagne N., Boucher C.A., Schapiro J.M., Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 353:1999;2195-2199.
28. Easterbrook P.J., Yu L.M., Goetghebeur E., Boag F., Mc Lean K., Gazzard B. Ten-year trends in CD4 cell counts at HIV and AIDS diagnosis in a London HIV clinic. AIDS. 14:2000;561-571.
29. Emlet C.A., Farkas K.J. Correlates of service utilization among midlife and older adults with HIV/AIDS: the role of age in equation. J. Aging Health. 14:2002;315-335.
30. Erickson J.W., Gulnick S.V., Markowitz M. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS. 13(Suppl. A):1999;S189-S204.
31. Falloon J. Salvage antiretroviral therapy. AIDS. 14(Suppl. 3):2000;209-217.
32. Floridia M., Tomino C., Bucciardini R., Ricciardulli D., Fragola V., Pirillo M., Amici R. A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection. AIDS Res. Hum. Retroviruses. 16:2000;1809-1820.
33. Freedberg K.A., Losina E., Weinstein M.C., Paltiel A.D., Cohen C.J., Seage G.R., Craven D.E., Zhang H., Kimmel A.D., Goldie S.J. The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med. 344:2001;824-831.
34. Gebo K.A., Chaisson R.E., Folkemer J.G., Bartlett J.G., Moore R.A. Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS. 13:1999;963-969.
35. Gebo K.A., Diener-West M., Moore R.D. Hospitalization rates in an urban cohort after the introduction of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 27:2001;143-152.
36. Gisolf E.H., Jurriaans S., Pelgrom J., Van Wanzaele F., Van der Ende M.E., Brinkman K., Borst M.J., De Wolf F., Japour A.J., Danner S.A. The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. AIDS. 14:2000;405-413.
37. Goetz M.B., Boscardin W.J., Wiley D., Alkasspooles S. Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy. AIDS. 15:2001;1576-1579.
38. Grabar S., Pradier C., Le Corfec S., Lancar R., Allavena C., Bentata M., Berlureau P., Dupont C., Fabbro-Peray P., Poizot-Martin I., Costagliola D. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 14:2000;141-149.
39. Graham N.M. Metabolic disorders among HIV-infected patients treated with protease inhibitors: a review. J. Acquir. Immune Defic. Syndr. 25(Suppl. 1):2000;S4-S11.
40. Gulick R.M., Mellors J.W., Havlir D., Eron J.J., Gonzalez C., McMahon D., Richman D.D., Valentine F.T., Jonas L., Meibohm A., Emini E.A., Chodakewitz J.A. Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:1997;725-733.
41. Hadigan C., Meigs J.B., Corcoran C., Rietschel P., Piecuch S., Basgoz N., Davis B., Sax P., Stanley T., Wilson P.W., D'Agostino R.B., Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin. Infect. Dis. 32:2001;130-139.
42. Harrigan P.R., Côte H.C.F. Clinical utility of testing human immunodeficiency virus for drug resistance. Clin. Infect. Dis. 30(Suppl. 2):2000;S117-S122.
43. Harrington M., Carpenter C.C. Hit HIV-1 hard, but only when necessary. Lancet. 355:2000;2147-2152.
44. Havlir D.V., Hellmann N.S., Petropoulos C.J., Whitcomb J.M., Collier A.C., Hirsch M.S., Tebas P., Sommadossi J.P., Richman D.D. Drug susceptibility in HIV infection after viral rebound in patients receiving indivinavir- containing regimens. JAMA. 283:2000;229-234.
45. Haynes B.F., Hale L.P., Weinhold K.J., Patel D.D., Liao H.X., Bressler P.B., Jones D.M., Demarest J.F., Gebrhard-Mitchell K., Haase A.T., Bartlett J.A. Analysis of the adult thymus in reconstruction of T lymphocytes in HIV-1 infection. J. Clin. Invest. 103:1999;453-456.
46. Hinkin C.H., Castellon S.A., Durvasula R.S. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 59:2002;1944-1950.
47. Kakuda T.N., Brundage R.C., Anderson P.L., Fletcher C.V. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS. 13:1999;2311-2312.
48. Kaplan J.E., Hanson D., Dworkin M.S., Frederick T., Bertolli J., Lindegren M.L., Halmberg S., Jones J.L. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin. Infect. Dis. 30(Suppl. 1):2000;S5-S14.
49. Keller M.J., Hausdorff J.M., Kyne L., Wei J.V. Is age a negative prognostic indicator in HIV infection or AIDS? Aging. 11:1999;35-38.
50. Khanna N., Klimkait T., Schiffer V., Irigoyen J., Telenti A., Hirschel R., Battegay M. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. AIDS. 14:2000;791-799.
51. Kumaranayake L., Watts C. Economic costs of HIV/AIDS prevention activities in sub-Saharan Africa. AIDS. 14(Suppl. 3):2000;239-252.
52. Law M.G., De Winter L., McDonald A., Cooper D.A., Kaldor J.M. AIDS diagnoses at higher CD4 counts in Australia following the introduction of highly active antiretroviral treatment. AIDS. 13:1999;263-269.
53. Ledergerber B., Egger M., Erard V., Weber R., Hirschel B., Furrer H., Battegay M., Vernazza P., Bernasconi E., Opravil M., Kaufmann D., Sudre P., Francioli P., Telenti A. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. The Swiss HIV Cohort Study. JAMA. 282:1999;2220-2226.
54. Linsk N.L. HIV among older adults: age specific issues in prevention and management. AIDS Read. 10:2000;430-440.
55. Lucas G.M., Chaisson R.E., Moore R.D. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann. Intern. Med. 131:1999;81-87.
56. Manfredi R. Management of dyslipidemia in patients with HIV disease. Clin. Microbiol. Infect. 6:2000;579-584.
57. Manfredi R. Evolution of HIV disease in the third millennium: clinical and related economic issues. Int. J. Antimicrob. Agents. 19:2002;251-253.
58. Manfredi, R., 2003. HIV infection, antiretroviral therapy, and hepatic function. Emerging epidemiological, pathogenetic, and clinical issues, and their consequences on disease management. AIDS, in press.
59. Manfredi R., Chiodo F. A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. AIDS. 14:2000a;1475-1477.
60. Manfredi R., Chiodo F. Switch to an antiretroviral treatment of expected lower potency after effective highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 23:2000b;95-98.
61. Manfredi R., Chiodo F. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate. J. Infect. 42:2001a;181-188.
62. Manfredi R., Chiodo F. Switch of protease inhibitor-containing HAART in routine clinical practice: a four-year prospective observational study. Int. J. STD AIDS. 12:2001;84-88.
63. Manfredi R., Pieri F., Pileri S.A., Chiodo F. The changing face of AIDS-related opportunism: cryptococcosis in the highly active antiretroviral therapy (HAART) era. Case reports and literature review. Mycopathologia. 148:1999;73-78.
64. Manfredi R., Calza L., Chiodo F. Lack of change in the distribution of AIDS-defining opportunistic diseases and the related degree of immunodeficiency during the periods before and after the introduction of highly active antiretroviral therapy. Eur. J. Clin. Microbiol. Infect. Dis. 20:2001a;410-413.
65. Manfredi R., Calza L., Chiodo F. Gynecomastia associated with highly active antiretroviral therapy. Ann. Pharmacother. 35:2001b;438-439.
66. Manfredi R., Calza L., Chiodo F. HIV disease among immigrants coming to Italy from outside of the European Union: a case-control study of epidemiological and clinical features. Epidemiol. Infect. 127:2001c;527-533.
67. Manfredi R., Calza L., Chiodo F. Three to seven concurrent AIDS-defining disorders at first hospitalization of AIDS presenters as an unexpected emerging feature during the era of highly active antiretroviral therapy. AIDS. 16:2002a;2356-2358.
68. Manfredi R., Motta R., Patrono D., Calza L., Chiodo F., Boni P. A prospective case-control survey of laboratory markers of skeletal muscle damage during HIV disease and antiretroviral therapy. AIDS. 16:2002b;1969-1971.
69. Manfredi, R., Battista, G., Sassi, C., Calza, L., Chiodo, F., Canini, R., 2003a. Morphofunctional evolution of thymus response after first-line combined antiretroviral therapy in adult HIV-infected patients. Med. Malad. Infect., in press.
70. Manfredi R., Calza L., Chiodo F. Antiretroviral treatment and advanced age: epidemiologic, laboratory, and clinical features in the elderly. J. Acquir. Immune Defic. Syndr. 33:2003b;112-114.
71. Manfredi R., Motta R., Patrono D., Calza L., Chiodo F., Boni P. A Frequency, risk factors, and features of hyperlactatemia in a large number of patients undergoing antiretroviral therapy. AIDS. 17:2003c;2131-2133.
72. Martínez E., Conget I., Lozano L., Casamitjana R., Gatell J.M. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS. 13:1999;805-810.
73. Mauss S. HIV-associated lipodystrophy syndrome. AIDS. 14(Suppl. 3):2000;S197-S207.
74. Max B., Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence. Clin. Infect. Dis. 30(Suppl. 2):2000;S96-S116.
75. Miller K.D., Cameron M., Wood L.V., Dalakas M.S., Kovacs J.A. Lactic acidosis and hepatic steatosis associated with use of stavudine administration: report of four cases. Ann. Intern. Med. 133:2000;192-196.
76. Mocroft A., Youle M., Moore A., Sabin C.A., Madge S., Lepri A.C., Tyrer M., Chaloner C., Wilson D., Loveday C., Johnson M.A., Phillips A.N. Reasons for modification and discontinuation of antiretroviral therapy. Results from a single treatment centre. AIDS. 15:2001;185-194.
77. Moore R.D. Cost effectiveness of combination HIV therapy: three years later. Pharmacoeconomics. 17:2000;325-330.
78. Moyle G.J., Back D. Principles and practice of HIV-protease inhibitor pharmacoenhancement. HIV Med. 2:2001;105-113.
79. Mulligan K., Grunfeld C., Tai V.W., Algren H., Pang M., Chernoff D.N., Lo J.C., Schambelan M. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 23:2000;35-43.
80. Murphy R.L., Sommadossi J.P., Lamson M., Hall D.B., Myers M., Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J. Infect. Dis. 179:1999;1116-1123.
81. Murphy R.L., Brun S., Hicks C., Eron J.J., Gulick R., King M., White A.C., Benson C., Thompson M., Kessler H.A., Hammer S., Bertz R., Hsu A., Japour A., Sun E. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS. 15:2001;1-9.
82. Mussini C., Pezzotti P., Govoni A., Borghi V., Antinori A., D'Arminio Monforte A., De Luca A., Mongiardo N., Cerri M.C., Chiodo F., Concia E., Bonazzi L., Moroni M., Ortona L., Esposito R., Cossarizza A., De Rienzo B. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency type 1-infected patients: the changes in opportunistic prophylaxis study. J. Infect. Dis. 181:2000;1635-1642.
83. Nieuwkerk P.T., Reijers M.H.E., Weigel H.M., Lange J.M., Sprangers M.A. Quality of life in maintenance vs. prolonged induction therapy for HIV. JAMA. 284:2000;178-179.
84. Pakker N.G., Kroon E.D.M.B., Roos M.T.L., Otto S.A., Hall D., Wit F.W., Hamann D., Van der Ende M.E., Claessen F.A., Kauffmann R.H., Koopmans P.P., Kroon F.P., Ten Napel C.H., Sprenger H.G., Weigel H.M., Montaner J.S., Lange J.M., Reiss P., Schellekens P.T., Miedema F. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS. 13:1999;203-212.
85. Palella F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:1998;853-860.
86. Paolucci S., Baldanti F., Maserati R., Castelli F., Suter F., Maggiolo F., Pan A., Gerna A. Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART. Antiviral Res. 45:2000;101-114.
87. Paredes R., Mocroft A., Kirk O., Lazzarin A., Barton S.E., Van Lunzen J., Katzenstein T.L., Antunes F., Lundgren J.D., Clotet B. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch. Intern. Med. 160:2000;1123-1132.
88. Paterson D.L., Swindells S., Mohr J., Brester M., Vergis E.N., Squier C., Wagener M.M. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133:2000;21-30.
89. Périard D., Telenti A., Sudre P., Cheseaux J.J., Halfon P., Reymond M.J., Marcovina S.M., Glauser M.P., Nicod P., Darioli R., Mooser V. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation. 100:1999;700-705.
90. Pialoux G., Raffi F., Brun-Vezinet F., Meiffredy V., Flandre P., Gastaut J.A., Dellamonica P., Yeni P., Delfraissy J.F., Aboulker J.P. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. N. Engl. J. Med. 339:1998;1269-1276.
91. Poulin J.F., Sékaly R.P. Function of the thymus in HIV-infected adults. JAMA. 282:1999;219.
92. Puoti M., Spinetti A., Ghezzi A., Donato F., Zaltron S., Putzolu V., Quiros-Roldan E. Mortality for liver disease in patients with HIV infection: a cohort study. J. Acquir. Immune Defic. Syndr. 24:2000;211-217.
93. Rezza G. Determinants of progression to AIDS in HIV-infected individuals: an update from the Italian Seroconversion Study. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 17(Suppl. 1):1998;S13-S16.
94. Rinaldi R., Manfredi R., Azzimondi G., Rodorigo G., Tonon C., De Rosa V., Mastroianni A., Coronado O.V., Legnani G., Chiodo F., D'Alessandro R. Recurrent "migrainelike" episodes in patients with HIV disease. Headache. 37:1997;443-448.
95. Saint-Marc T., Partisani M., Poizot-Martin I., Ruoviere O., Bruno F., Avellaneda R., Lang J.M., Gastaut J.A., Touraine J.L. Fat redistribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 14:2000;37-49.
96. Samet J.H., Freedberg K.A., Savetsky J.B., Sullivan L.M., Padmenabhan L., Stein M.D. Understanding delay to medical care for HIV infection: the long-term non-presenter. AIDS. 15:2001;77-85.
97. Shah S.S., McGowan J.P., Smith S., Blum S., Klein R.S. Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in Nwe York City. Clin. Infect. Dis. 35:2002;1243-1248.
98. Shulman N.S., Zolopa A.R., Passaro D.J., Murlidharan V., Istraelski D.M., Brossant C.L., Miller M.D., Van Doren S., Shafer R.W., Katzenstein D.A. Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response. J. Acquir. Immune Defic. Syndr. 23:2000;221-226.
99. Smith K.Y., Valdez H., Landay A., Spritzler J., Kessler H.A., Connick E., Kuritzkes D., Gross B., Francis I., McCune J.M., Lederman M.M. Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine and ritonavir therapy. J. Infect. Dis. 181:2000;141-147.
100. Soriano V., Castilla J., Gomez-Cano M., Holguin A., Villalba N., Mas A., Gonzalez-Lahoz J. The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load. J. Infect. 36:1998;307-311.
101. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., Stryker R., Johnson P., Labriola D.F., Farina D., Manion D.J., Ruiz N.M. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N. Engl. J. Med. 341:1999;1865-1873.
102. Tan H.H., Chan R.K., Goh C.L. Sexually transmitted diseases in the older population in Singapore. Ann. Acad. Med. Singapore. 31:2002;493-496.
103. Tantisiriwat W., Tebas P., Polish L.B., Casabar E., Powderly W.G., Fichtenbaum C.J. Elevated lactate levels in hospitalized persons with HIV infection. AIDS Res. Hum. Retroviruses. 17:2001;195-201.
104. Tebas P., Powderly W.G., Claxton S., Marin D., Tantisiriwat W., Teitelbaum S.L., Yarasheski K.E. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 14:2000;F63-F67.
105. 1999 USPHS/IDSA, 2000 Guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. Clin. Infect. Dis. 30 (Suppl. 1), S29-S65.
106. Verucchi G., Calza L., Manfredi R., Chiodo F. Incidence of liver toxicity in HIV-infected patients receiving isolated dual nucleoside analogue antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 33:2003;546-548.
107. Viganò A., Vella S., Saresella M., Vanzulli A., Bricalli S., Di Fabio S., Ferrante P., Andreotti M., Pirillo L., Dally L.G., Clerici M., Principi N. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS. 14:2000;251-261.
108. Von Giesen H.J., Hefter H., Jablonowski H., Arendt G. Stavudine and the peripheral nerve in HIV-1 infected patients. J. Neurol. 246:1999;211-217.
109. Wit W.N.M., Van Leeuwen R., Weverling G.J. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodefiency virus type 1-infected persons. J. Infect. Dis. 179:1999;790-798.
110. Zablotsky D.L. Overlooked, ignored and forgotten: older women at risk for HIV infection and AIDS. Res. Aging. 20:1998;760-766.
111. Zhang L., Lewin S.R., Markowitz M., Lin H.H., Skulsky E., Karanicolas R., He Y., Jin X., Tuttleton S., Vesanen M., Spiegel H., Kost R., Van Lunzen J., Stellbrink H.J., Wolinsky S., Borkowsky W., Palumbo P., Kostritis L.G., Ho D.D. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J. Exp. Med. 190:1999;725-732.